In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
After finishing at $28.47 in the prior trading day, Myriad Genetics, Inc. (NASDAQ: MYGN) closed at $28.29, down -0.63%. In other words, the price has decreased by -$0.63 from its previous closing price. On the day, 0.66 million shares were traded. MYGN stock price reached its highest trading level at $29.1399 during the session, while it also had its lowest trading level at $27.994.
Ratios:
Our goal is to gain a better understanding of MYGN by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.78 and its Current Ratio is at 1.96. In the meantime, Its Debt-to-Equity ratio is 0.19 whereas as Long-Term Debt/Eq ratio is at 0.18.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Morgan Stanley on September 19, 2024, initiated with a Equal-Weight rating and assigned the stock a target price of $32.
On August 28, 2024, Wells Fargo started tracking the stock assigning a Overweight rating and target price of $35.
On June 27, 2024, Scotiabank started tracking the stock assigning a Sector Outperform rating and target price of $29.Scotiabank initiated its Sector Outperform rating on June 27, 2024, with a $29 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 21 ’24 when Ancona Margaret bought 11,538 shares for $27.82 per share.
DIAZ PAUL J sold 15,000 shares of MYGN for $400,800 on Sep 11 ’24. The President and CEO now owns 977,378 shares after completing the transaction at $26.72 per share. On Sep 11 ’24, another insider, Muzzey Dale, who serves as the Chief Scientific Officer of the company, sold 2,100 shares for $26.17 each. As a result, the insider received 54,961 and left with 108,013 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MYGN now has a Market Capitalization of 2580195072 and an Enterprise Value of 2615307776. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.20 while its Price-to-Book (P/B) ratio in mrq is 3.47. Its current Enterprise Value per Revenue stands at 3.26 whereas that against EBITDA is -53.374.
Stock Price History:
Over the past 52 weeks, MYGN has reached a high of $29.30, while it has fallen to a 52-week low of $13.82. The 50-Day Moving Average of the stock is 3.41%, while the 200-Day Moving Average is calculated to be 22.88%.
Shares Statistics:
The stock has traded on average 777.40K shares per day over the past 3-months and 646020 shares per day over the last 10 days, according to various share statistics. A total of 89.90M shares are outstanding, with a floating share count of 87.20M. Insiders hold about 3.99% of the company’s shares, while institutions hold 101.98% stake in the company. Shares short for MYGN as of 1724976000 were 3943125 with a Short Ratio of 5.07, compared to 1722384000 on 4389034. Therefore, it implies a Short% of Shares Outstanding of 3943125 and a Short% of Float of 6.08.
